Sobi stays on its acquisitive streak with $915m Dova deal

Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova

AZ buys cut price priority review voucher, but for what?

Sobi cuts staff and buys Novimmune drug in refocus

Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune.

Sobi buys AstraZeneca's RSV virus drug for $1.5bn

Sobi has completed the acquisition of AstraZeneca’s Synagis (palivizumab) for $1.5 billion in cash and shares, plus certain conditional payments.

FDA approves Sobi's Gamifant for rare, fatal childhood disea...

The FDA has approved Sobi's Gamifant, a treatment for primary hemophagocytic lymphohistiocytosis (HLH).

AZ sells rights to RSV virus drug to Sobi for $1.5bn

AstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for an upfront $1.5 billion in cash and shares, plus certain conditional payme